Safety, Tolerability, and Pharmacokinetics of HRS-3802 Monotherapy in Patients With Malignant Solid Tumors: a Single-arm, Open, Multicenter Phase I Study

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 20 Feb 2025

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

13 Feb 2025 Status changed from not yet recruiting to recruiting.
04 Feb 2025 According to a Jiangsu Hengrui Medicine Co. media release, the clinical trial application for HRS-3802 sustained-release tablets, which was accepted on September 18, 2018, has been approved by the Food and Drug Administration ("FDA") of China and the "Notice of Approval for Clinical Trial of Drugs" for HRS-3802 sustained-release tablets, has been issued.
20 Jan 2025 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com